The OActive project intends to make a significant leap forward adopting a multi-scale holistic analysis where patient-specific information from various levels, including molecular (e.g. biochemical/inflammatory biomarkers), cell, tissue and whole body, will be integrated and combined with information from other sources such as, environmental, behavioural and social risk factors to generate robust predictors for new personalised interventions for delaying onset and/or slowing down progression of OA.
OActive targets patient-specific OA prediction and interventions by using a combination of mechanistic computational models, simulations and big data analytics. Once constructed, these models will be used to simulate and predict optimal treatments, better diagnostics, and improved patient outcomes, overcoming the limitation of the current treatment interventions, Augmented Reality (AR) empowered interventions will be developed in a personalised framework allowing patients to experience the treatment as more enjoyable, resulting in greater motivation, engagement, and training adherence. The AR element will also be helpful for the therapists for validating the patients’ progress and allow them a more adaptive rehabilitation therapy in terms of flexible interactive content.
ΟΑctive at a glance
OActive’s mission is to improve healthcare by transforming and accelerating the OA diagnosis and prediction based on a more comprehensive and holistic understanding of disease pathophysiology, dynamics, and patient outcomes.
The OActive scientific and technological objectives focus on the development of computer-based predictive models and simulation for understanding the onset and progression of a major disease like OA.
OActive is planned as a 36-month project and its realisation will be achieved in ten (10) WPs, including: R&D activities (WP2-6), Validation activities (WP7-9), Dissemination & Exploitation Activities (WP10), Project management activities (WP1).
The OActive project is expected to offer the medical care sector a solution that will predict, delay the onset and slow down the progression of OA offering patients an increased quality of life.